Items tagged with Prevention

RESIST-TB webinar: VQUIN and TB-CHAMP results (post)

RESIST-TB will host a webinar on 11 April 2024 to present results from the two randomized, controlled trials -- VQUIN and TB-CHAMP -- that used levofloxacin for preventive therapy in adult and pediatric household contacts of people with multidrug- and rifampicin-resistant TB (MDR/RR-TB).

1/4/6x24 Mid-campaign report launch webinar - recording now available online (post)

The 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar on 27 March 2024 to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments. The report highlights progress and gaps in scaling up access to shorter, safer TB regimens — one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.

Who should receive preventive treatment for TB? Individuals of all ages with positive skin or blood test (post)

A new study suggests that countries should prioritize treatment for exposed individuals with evidence of TB infection, regardless of age — except in high-burden settings, where all exposed individuals should be considered for treatment.

South Africa: Slow progress after decision to make TB prevention pills more widely available (post)

Besides preventing illness and death, TB preventive treatment (TPT) is estimated to be highly cost-effective. Yet, uptake of TPT is not what it could be in South Africa. Tiyese Jeranji asks how much has changed since the Department of Health last year decided to make TPT much more widely available.

TB preventive therapy: What factors influence treatment discontinuation? (post)

Although time to treatment discontinuation did not significantly differ between patients with latent tuberculosis on the basis of treatment regimen, interruptions in therapy varied by social and demographic factors.

(post with image)

Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource- constrained settings (document)

These guidelines from the WHO deal with isoniazid preventative therapy (IPT) in people with HIV. The guidelines make 12 recommendations including the provision of IPT for 36 months where there is capacity to do so. Controversially, these guidelines do not require tuberculin skin testing.

Guidelines for Tuberculosis Preventative Therapy among HIV individuals of South Africa (document)

These guidelines outline eligibility requirements and standard of procedure for prescribing Isoniazid Preventative Therapy (IPT) given an individual's TB and HIV status in South Africa. They are updated to include the current South African mandate which no longer requires the use of the tuberculin skin test to identify HIV infected people eligible for IPT. As authorized, "all HIV-infected people showing no signs or symptoms suggestive of active TB are eligible for TB prevention therapy." Also included are recommendations for regime dosage and duration as well as when and how to start.

Tuberculosis Strategic Plan for South Africa 2007-2011 (document)

These guidelines provide a strategic framework for what needs to be done to reduce the burden of TB in South Africa. The plan emphasizes implementing a coordinated multi-sectoral approach and highlights the need for: availability of adequate resources especially skilled human resources, sustained funding, partnership building, community mobilisation. Additionally, as stated in document "[f]ighting poverty to accelerate economic and social growth is critical for the success of this plan." It addresses the importance of having a functional integration of TB and HIV activities at facility level as well as priority infection control measures for MDR and XDR-TB.

National Policy Guidelines for HIV/TB Collaborative Activities (document)

This policy document responds to a demand from service providers and other partners for guidance on how to implement TB/HIV collaborative activities. It is complementary to and synergistic with the established core activities of tuberculosis and HIV/AIDS prevention and control programmes. The policy objectives include: establishing the mechanisms for sharing information and collaboration in planning, implementation, monitoring and evaluation of tuberculosis and HIV/AIDS programmes at all levels of health services; to screen all HIV patients for TB and provide preventive and curative care for those with latent and active TB respectively and to provide HIV screening to all TB patients and comprehensive HIV care services to those co-infected with HIV.